Semaglutide and Cardiovascular Risk Reduction: What the Latest Data Tell Us ByAlexandra Gerlach, Associate Editor,John B. Buse, MD, PhDMarch 30th 2025John Buse, MD, PhD discusses the expanding role of GLP-1 receptor agonists in treatment of cardiovascular conditions.